Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Atossa Therapeutics, Inc.ATOS · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required |
| Reliability | 0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| Peer failure rate | 1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $12.5M to $120M assetstotal assets $47.6M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | thin data, degenerate inputs · fortress balance sheetnot computable: distress |
| Inputs computable | 5 of 14 |
| Graded from | filings received through Mar 25, 2026198 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $2.422026-10-08; market equity $24.1M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 25, 2026; the document on sec.gov.
We are a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and other breast conditions. Our lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator (SERM)/ selective estrogen receptor degrader (SERM/D) currently in Phase 2 clinical development. The Company is evaluating potential indications for (Z)-endoxifen based on its pharmacologic profile, including its potential for both reducing the risk of and for the treatment of breast cancer, as well as in other therapeutic areas. We have been granted U.S.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 48.0 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31 | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| a prior annual debt, equity, and cash observation is required | |||||||
| Accruals ratio | (8.1%) | [1,5-7] | (6.6%) | 48.0 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 4 | |||||||
| Solvency, sleeve percentile 49.0 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | (11.97) | [1,8-13] | (0.31) | 64.9 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| EBITDA must exceed $100,000 | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| interest expense must exceed $100,000 | |||||||
| Current ratio | 5.53x | [8-9] | 2.96x | 33.1 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 51.4 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| NOPAT must exceed $100,000 | |||||||
| Asset growth, three years | (27.2%) | [1,7,14-15] | 2.1% | 90.9 | 704 | 2025-12-31 | |
| Net share issuance, one year | (0.03%) | [16-17] | 2.5% | 11.8 | 634 | 2026-03-17 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (80.8%) | 8.0% | 4 | hotter than 4 of 100 peers |
| Distance from 52-week high | (86.3%) | (31.4%) | 5 | closer to its high than 5 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | enterprise value must exceed $100,000 | |
| Free cash flow yield | (123.3%) | (1.0%) | 5 | pricier than 95 of 100 peers |
| Book value to price | 1.11 | 0.28 | 89 | pricier than 11 of 100 peers |
| Sales to price | 0.00 | 0.31 | 1 | pricier than 99 of 100 peers |
| Composite equity issuance, five years | 21.4% | 20.3% | 51 | more equity-funded than 51 of 100 peers |
| Relative strength against the sector, log excess return | (1.86) | (0.14) | 4 | ahead of 4 of 100 peers |
Inputs: market equity $24.1M; EBIT -$37.1M; free cash flow -$29.8M; book equity $26.8M; sales $1,758; debt $0; cash $26.1M[18].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (45.5%) | ✗ fail[5,7] |
| Operating cash flow above zero | -$29.8M | ✗ fail[6] |
| Return on assets improved | (19.0 pts) | ✗ fail[5,7,14,19] |
| Operating cash flow exceeds net income | $5.0M | ✓ pass[5-6] |
| Long-term leverage fell | n/a[1,7,14] | |
| Current ratio improved | (946.4 pts) | ✗ fail[8-9,20-21] |
| No new shares issued | (0.0%) | ✓ pass[16-17] |
| Gross margin improved | n/a | |
| Asset turnover improved | n/a[7,14] | |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $26.1M[22] |
| Operating cash flow, four quarters | -$35.8M[6,22-26] |
| Months of runway | 8.8 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 63 |
| 10-Q received Aug 7, 2026 | |
| Median daily dollar volume | $132,179 |
| 63 sessions | |
| Days since newest grade input | 198 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $47.6M | 2025-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:SalesRevenueNet | $1,758 | 2015-12-31 | 2017-03-21 | 10-K/A | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $8.5M | 2014-12-31 | 2017-03-21 | 10-K/A | filing · viewer · series |
| 4 | total debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $49,216 | 2014-12-31 | 2015-03-30 | 10-K | filing · viewer · series |
| 5 | net income | us-gaap:NetIncomeLoss | -$34.8M | 2025-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 6 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$29.8M | 2025-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 7 | assets | us-gaap:Assets | $76.4M | 2024-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 8 | current assets | us-gaap:AssetsCurrent | $45.6M | 2025-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 9 | current liabilities | us-gaap:LiabilitiesCurrent | $8.3M | 2025-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 10 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$246.6M | 2025-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$37.1M | 2025-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 12 | book equity | us-gaap:StockholdersEquity | $39.4M | 2025-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 13 | liabilities | us-gaap:Liabilities | $8.3M | 2025-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 14 | assets | us-gaap:Assets | $96.3M | 2023-12-31 | 2025-03-25 | 10-K | filing · viewer · series |
| 15 | assets | us-gaap:Assets | $123.5M | 2022-12-31 | 2024-04-01 | 10-K | filing · viewer · series |
| 16 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 8,611,361 | 2026-03-17 | 2026-03-25 | 10-K | filing · viewer · series |
| 17 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 129,170,004 | 2025-03-17 | 2025-03-25 | 10-K | filing · viewer · series |
| 18 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 9,979,298 | 2026-07-31 | 2026-08-07 | 10-Q | filing · viewer · series |
| 19 | net income | us-gaap:NetIncomeLoss | -$25.5M | 2024-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 20 | current assets | us-gaap:AssetsCurrent | $74.5M | 2024-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 21 | current liabilities | us-gaap:LiabilitiesCurrent | $5.0M | 2024-12-31 | 2026-03-25 | 10-K | filing · viewer · series |
| 22 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $26.1M | 2026-06-30 | 2026-08-07 | 10-Q | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$19.2M | 2026-06-30 | 2026-08-07 | 10-Q | filing · viewer · series |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$9.6M | 2026-03-31 | 2026-05-08 | 10-Q | filing · viewer · series |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$19.2M | 2025-09-30 | 2025-11-12 | 10-Q | filing · viewer · series |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$13.2M | 2025-06-30 | 2026-08-07 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
